vVARDIS raises €31.5M Series A round

11 February 2025· Zug, Switzerland· health, dental_care, biomimetic, biotech, deep_tech, b2b

The capital will support the company's growth initiatives and global commercial expansion of its innovative drill-free treatment for early tooth decay, Curodont™.

Investors

LeadOrbiMed

About vVARDIS

Stage
Series C
Headquarters
Zug, Switzerland
Founded
2003
Team Size
51–200
Sectors
healthdental_carebiomimeticbiotechdeep_techb2b

Source: https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH7z7LTtq3RMbDSY7qm1-dtV9K2NZjwoJFnVq48UtGogQRZSbYvqySGflWCKiObOtlxl4Ch26hj9N6o7kGdeynMQWhik_HKGjuXuIWllEnrGBw8EEiLYlaTF3oHUvcY7nBNdAE3-gL7GYB_EG-94iuJGVIzIUct4K-uvNXgXMQalWdiDZPKULzUIX3xlsyW8bpAW5eLEXGFOsOBXup0y-OtqVVvZzT9